Dar-win schreef op 30 augustus 2017 21:44:
@galajurk:
LEIDEN, the Netherlands, Aug. 29, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that dosing of cystic fibrosis patients in its Phase 1b clinical trial of QR-010 has been completed and top-line data are scheduled to be announced post-market close on Monday, September 25, 2017.
Zitten dus ook op CF. Ben ook zeer benieuwd naar hún vorderingen.
Zit zelf wel zwaarder in glpg dan in proqr.